Received Sep 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PNC21 | PNEUMO (CAPVAXIVE) | MERCK & CO. INC. | UNK | Z006076 | OT |
| PNC21 | PNEUMO (CAPVAXIVE) | MERCK & CO. INC. | UNK | — | OT |
Confimed patient not symptomatic. No additional AE; extra dose of CAPVAXIVE administered to patient on 08/05/2025; This spontaneous report was received from a physician assistant and refers to a 66-year-old patient of unknown gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On an unknown date, the patient was vaccinated with a dose of Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE) (dose, route of administration, anatomical site, lot # and expiration date were not reported) as prophylaxis. Then, on 05-Aug-2025, the patient received an extra dose of Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE) (lot #Z006076, expiration date: 11-Sep-2026) (dose, route of administration and anatomical site were not reported) as prophylaxis (Extra dose administered). No additional adverse event (No adverse event). Batch/Lot number is being requested and will be submitted if received.